A Hong Kong co-led global study has found that a targeted therapy can keep more than half of advanced lung cancer patients alive without disease progression for at least seven years, marking a step towards turning the deadly illness into a chronic condition. Researchers from the Chinese University of Hong Kong on Wednesday released the findings of their study, which looked into the efficacy of the third-generation targeted therapy lorlatinib on patients with advanced lung cancer. The study...
In the second of a six-part Health Matters wellness series on cancer in Hong Kong, Elizabeth Cheung examines the rise of lung cancer among women, the risk factors beyond smoking and growing calls for earlier detection. Rates of new lung cancer cases among Hong Kong women have risen by 20 per cent in the past two decades despite their smoking less than men, a South China Morning Post review has found, prompting calls for citywide screenings to catch the disease earlier. Experts said genetic...
Akeso, whose drug ivonescimab was hailed as biotech’s “DeepSeek moment” amid US competition last year, announced better-than-expected clinical results showing it can treat a type of lung cancer commonly found in smokers, potentially expanding its approved uses. Analysts suggest it could become a backbone therapy in the US$20 billion global non-small cell lung cancer market and have revised their target prices upwards. The drug’s phase three trial found that ivonescimab reduced the risk of death...